Cogent Biosciences, Inc.
COGT
Rangering i aksjer
#3364
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Aksjekurs
$29.79
Markedsverdi
$5.17B
Endring (1 dag)
0.90%
Endring (1 år)
81.73%
Land
US
Handel Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
EPS for Cogent Biosciences, Inc. (COGT)
EPS per June 2026 TTM: $-2.31
Ifølge de siste økonomiske rapportene og aksjekursen til Cogent Biosciences, Inc. er selskapets nåværende EPS (TTM) $-2.31. Ved slutten av 2023 hadde selskapet en EPS på $-2.42, en økning sammenlignet med EPS-en i 2022 som var $-2.26.
EPS-historikk for Cogent Biosciences, Inc. fra 2015 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-2.31 | -6.10% |
| 2024 | $-2.46 | 1.65% |
| 2023 | $-2.42 | 7.08% |
| 2022 | $-2.26 | 22.16% |
| 2021 | $-1.85 | -69.17% |
| 2020 | $-6.00 | 51.13% |
| 2019 | $-3.97 | -28.47% |
| 2018 | $-5.55 | 60.87% |
| 2017 | $-3.45 | 11.29% |
| 2016 | $-3.10 | 174.34% |
| 2015 | $-1.13 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -849.78% |
US
|
|
| $-7.98 | 245.45% |
US
|
|
| $-5.29 | 129.00% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,300.87% |
NL
|
